Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-Sn-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
Cancer - United States
doi 10.1002/cncr.30789
Full Text
Open PDFAbstract
Available in full text
Date
May 30, 2017
Authors
Publisher
Wiley